key: cord-0797769-s2x99hhq authors: Focosi, Daniele; Franchini, Massimo title: Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment date: 2021-04-20 journal: Eur J Haematol DOI: 10.1111/ejh.13630 sha: f4a39acb06eee4129eb680a171854f08533658b7 doc_id: 797769 cord_uid: s2x99hhq While COVID‐19 convalescent plasma (CCP) efficacy is still under investigation in randomized controlled trials (RCT), CCP collections continue worldwide with largely variable criteria. Since it is well known that only a minority of patients develop high‐titer neutralizing antibodies (nAb), as assessed by the viral neutralization tests (VNT), strategies to maximize cost‐effectiveness of CCP collection are urgently needed. A growing amount of the population is having exposure to the virus and is hence becoming a candidate CCP donor. Laboratory screening with high‐throughput serology has good correlations with the VNT titer, but upstream screening using clinical surrogates would be advisable. We review here the existing literature on clinical predictors of high‐titer nAb. Older age, male sex, and hospitalization are the main proxies of high VNT and should drive CCP donor recruitment. The ongoing COVID-19 pandemic has caused more than 124 million cases and more than 2.5 million deaths worldwide as of March 2021. To date, there is only one drug whose efficacy has been unequivocally demonstrated in randomized controlled trials (RCT), namely dexamethasone. Many promising therapeutics have failed under RCTs, with COVID-19 convalescent plasma (CCP) having shown clinical benefit if used within 72 hours and with high neutralizing antibodies (nAb) titers; 1-6 on the contrary, trials lacking one of these requirements have failed to show clinical benefit. 1, [7] [8] [9] Many more trials are still ongoing. CCP donations can be used in different ways, 10 and nAb titers, despite detectable at more than 8 months, 11 show a decline with time after recovery: 12 Hence CCP donor recruitment is being pursued to create bulk storages. The cost for processing a CCP donation is considerably high due to personnel (donation nurses and laboratory technicians) and, in many regions, accessory testing (additional NAT, viral neutralization tests (VNT)), and pathogen reduction technologies. Additional concerns come from the risk of medical litigations in case of accidents during poorly selected CCP donations or prolonged storage of lowantibody units finally destined to discard. A review of the literature about clinical predictors of PRNT in COVID-19 was done following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines. 13 PubMed (www.pubmed.gov), medrXiv (https://www.medrx iv.org), and biorXiv (https://www.biorx iv.org/) online databases were systematically searched. The search included articles from January 1, 2020 up to February 5, 2021 . No restriction was placed on sample size. Only articles written in English were considered. The search query: "COVID19" AND "neutralizing" AND ("predictors" OR "proxies") was used for the first screening. The 293 search results were manually screened for consistency. The clinical parameters identified include age at diagnosis, days after initial diagnosis (positive nasopharyngeal swab), gender, hospitalization, and body mass index (BMI). Additionally, being largely available laboratory parameters, ABO blood group, and complete blood count were included as pseudo-clinical parameters. 16 Although it has been proposed that higher antibody levels in male and older patients simply relate to COVID-19 severity, 19 their model proposes that they remain associated with higher nAb titer levels after adjusting for hospitalization. In the largest study published so far by Del Fante and colleagues on 494 Italian CCP donors, the nAb titer was found to correlate positively with age and disease severity and negatively with female sex. 20 The VNT, while being a gold standard for nAb tittering, is a BSL3requiring and time-consuming method whose high-throughput vari- Nevertheless, the 13 studies we analyzed support the feasibility of first-line screening with cost-free clinical surrogates such as age, sex, and hospitalization to identify the convalescents who are most likely to have high nAb titers as later measured by VNT. In resource-constrained settings, it is hence possible to orient the wave of CCP donations so that time and resource wasting is minimized. This study was limited to clinical proxies, but several studies identified additional, serological (eg, anti-Spike IgG avidity, r = . 4, 22 or microfluidic affinity) 23 or non-serological biomarkers (eg, high Creactive protein, r = .5) 15 : The utility of such specialistic laboratory biomarkers is reduced by their limited availability at the time of CCP donation screening, and, if unavailable, by their incremental cost, which largely overlap the one of high-throughput serology. In most studies several patients (ranging from 2% in ICU to 25% in non-hospitalized patients 14, 15, 24, 25 to 40% in healthcare workers) 26 show no nAb at all as assessed by the VNT. Lee et al reported that S-specific antibodies are capable of engaging dimeric FcγRIIa and FcγRIIIa decay linearly over time. S-specific antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP) activity within plasma decline linearly as well, in line with the decay of S-specific IgG. Although there was significant decay in Sspecific plasma ADCC and ADP activity, they remained readily detectable by all assays in 94% at 149 days, in contrast to nAbs, which were only detectable in 70%. 27 While this does not mean at all that the convalescents are not protected from further exposures (having immunity from specific T-lymphocytes), 28 this circumstance further increases the need for cost-effective screening strategies. On average, the nAb titer peaks 30 days after symptom onset and declines by 25% every 15 days 17 (largely due to the decline in neutralizing IgM and IgA). 29, 30 It is therefore sounding that the days since positive nasopharyngeal swab correlates with the nAb titer. Nevertheless there is large variability in decline kinetics. Grzelak et al showed that the decline in nAbs was faster in males than in females, independently of age and BMI. 31 Titers ≥1:160 (which are considered the only useful donations for achieving clinical benefit) begin to decline significantly since day 60 (ie, 30 days after the peak). 32 Wendel et al reported that Ab titers ≥160 had a median persistence of 77 days after the onset of symptoms, but only 25% remained at this level after 100 days. 33 While decline around day 100 occurs in 90% of convalescents, 34 there was a high probability of sustaining nAb titers ≥160 when the initial nAb titer was ≥1280, weight ≥90kg, or BMI classified as overweight or obese. There was no correlation between ABO group, ABO isoagglutinin titers and persistent high nAb titers. 33 Of course, the initial nAb titer is only useful to evaluate the opportunity for repeated CCP donations. Several SARS-CoV-2 variants are emerging, 35-37 and the efficacy of anti-Spike monoclonal antibodies against them seems lower than CCP. 38 Since even the currently marketed anti-Spike vaccines are likely to offer reduced protection against some of these variants, 39 the interest in CCP is likely to remain high for months. We anticipate that, with a growing population of convalescents, screening for CCP donation eligibility on the basis of clinical predictors will anticipate laboratory screening with both high-throughput serology and VNT, especially in resource-poor settings. Additionally, collecting CCP from vaccinees is an intriguing opportunity, although to date the FDA is only allowing collection from vaccinees who have also been convalescents in the last 6 months. 40 Gaining knowledge about the breadth and duration of the immune response in COVID-19 vaccinees will likely contribute changing such regulations. We declare we have no conflict of interests to disclose. DF designed the paper, analyzed the data, and wrote the first draft. MF revised the final version. https://orcid.org/0000-0001-8811-195X A randomized trial of convalescent plasma in covid-19 severe pneumonia RECOVERY trial closes recruitment to convalescent plasma treatment for patients hospitalised with COVID-19 Early high-titer plasma therapy to prevent severe COVID-19 in older adults Convalescent plasma antibody levels and the risk of death from COVID-19 Timing of convalescent plasma administration and 28-day mortality for COVID-19 pneumonia. medRxiv Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. medRxiv Convalescent plasma in the management of moderate COVID-19 in India: open-label parallelarm phase II multicentre randomized controlled trial (PLACID Trial) Convalescent Plasma for COVID-19. A randomized clinical trial. medRxiv What is the optimal usage of COVID-19 convalescent plasma donations Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Viral infection neutralization tests: A focus on severe acute respiratory syndromecoronavirus-2 with implications for convalescent plasma therapy Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement Fever, diarrhea, and severe disease correlate with high persistent antibody levels against SARS-CoV-2. medrXiv Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications Convalescent plasma for COVID-19: male gender, older age and hospitalisation associated with high neutralising antibody levels Longitudinal analysis of clinical serology assay performance and neutralising antibody levels in COVID19 convalescents SARS-CoV-2 neutralization and serology testing of COVID-19 convalescent plasma from donors with nonsevere disease Considering how biological sex impacts immune responses and COVID-19 outcomes A retrospective study assessing the characteristics of COVID-19 convalescent plasma donors and donations Clinical predictors of donor antibody titre and correlation with recipient antibody response in a COVID-19 convalescent plasma clinical trial SARS-CoV-2 antibody avidity responses in COVID-19 patients and convalescent plasma donors Microfluidic affinity profiling reveals a broad range of target affinities for anti-SARS-CoV-2 antibodies in plasma of COVID survivors Neutralizing antibody response in non-hospitalized SARS-CoV-2 patients A longitudinal study of SARS-CoV-2-infected patients reveals a high correlation between neutralizing antibodies and COVID-19 severity Neutralizing antibody against SARS-CoV-2 spike in COVID-19 patients, health care workers and convalescent plasma donors Decay of Fc-dependent antibody functions after mild to moderate COVID-19 Cellular Immunity in COVID-19 Convalescents with PCR-Confirmed Infection but with Undetectable SARS-CoV-2-Specific IgG Neutralizing and binding antibody kinetics of COVID-19 patients during hospital and convalescent phases Role of Immunoglobulin M and A Antibodies in the Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2. The Journal of Infectious Diseases Sex differences in the evolution of neutralizing antibodies to SARS-CoV-2 Limited window for donation of convalescent plasma with high live-virus neutralizing antibody titers for COVID-19 immunotherapy A longitudinal study of convalescent plasma (CCP) donors and correlation of ABO group, initial neutralizing antibodies (nAb), and body mass index (BMI) with nAb and anti-nucleocapsid (NP) SARS-CoV -2 antibody kinetics: Proposals for better quality of CCP collections Clinical, laboratory, and temporal predictors of neutralizing antibodies against SARS-CoV-2 among COVID-19 convalescent plasma donor candidates Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations A preliminary selection analysis of the South African V501.V2 SARS-CoV-2 clade The impact of Spike mutations on SARS-CoV-2 neutralization mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants FDA. Recommendations for Investigational COVID-19 Convalescent Plasma Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population Characterization of 100 sequential SARS-CoV-2 convalescent plasma donations Screening for SARS-CoV -2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program Low serum neutralizing anti-SARS-CoV-2 S antibody levels in mildly affected COVID-19 convalescent patients revealed by two different detection methods Anti-SARS-CoV-2 antibody responses in convalescent plasma donors are increased in hospitalized patients; subanalyses of a phase 2 clinical study. Microorganisms Kinetics of viral load and antibody response in relation to COVID-19 severity Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment